Talking about Naloxone survey

Three-Month Survey: Module WB4518, Talking about Naloxone

                                                                                                                                                      OMB Control No. 0920-1050          

                                                                                                                                                                  Exp. Date 06/30/2025

The public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to - CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333 ATTN: PRA (0920-1050)

Now that it has been approximately three months since your completion of the CDC training module WB4518, Talking about Naloxone, we are interested in understanding how you have applied what you learned. Please take a moment to complete this short survey and provide your feedback in the comment boxes below.

	Survey Statement	Response Options
	As a result of taking the training module, I feel more knowledgeable about the role of naloxone in preventing overdoses.	Strongly Agree, Agree, Neither Agree, nor Disagree, Disagree, Strongly Disagree
	As a result of taking the training module, I can better identify risk factors for opioid-related harms.	Strongly Agree, Agree, Neither Agree, nor Disagree, Disagree, Strongly Disagree
	As a result of taking the training module, I feel more confident initiating conversations with patients about naloxone.	Strongly Agree, Agree, Neither Agree, nor Disagree, Disagree, Strongly Disagree
	As a result of taking the training module, I feel more confident educating patients on overdose risks and the role of naloxone in prevention.	Strongly Agree, Agree, Neither Agree, nor Disagree, Disagree, Strongly Disagree
	As a result of taking the training module, I feel more confident communicating about naloxone in a caring, compassionate, and non-stigmatizing manner.	Strongly Agree, Agree, Neither Agree, nor Disagree, Disagree, Strongly Disagree
	As a result of taking the training module, I feel more confident in addressing concerns, questions, or barriers related to naloxone use with patients and caregivers.	Strongly Agree, Agree, Neither Agree, nor Disagree, Disagree, Strongly Disagree
7.	As a result of taking the training module, my team has benefited from the knowledge and skills I acquired.	Strongly Agree, Agree, Neither Agree, nor Disagree, Disagree, Strongly Disagree
	Since completing the training module, I have more conversations with patients about naloxone.	Strongly Agree, Agree, Neither Agree, nor Disagree, Disagree, Strongly Disagree
	Since completing the training, I have more conversations with my patients about the risks associated with opioid use.	Strongly Agree, Agree, Neither Agree, nor Disagree, Disagree, Strongly Disagree
	What specific changes have you made, or actions have you taken since completing the training?	Open Ended (Text Box)
	What, if any, barriers have you encountered in applying what you learned? Please describe.	Open Ended (Text Box)
	What additional resources or support would help you to effectively implement the content of this training?	Open Ended (Text Box)